European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment — update 2026
Updated European guidance now recommends immunotherapy as standard treatment for advanced skin cancer, marking a major shift from older approaches.
The 2026 update of the European EADO/EDF/ESTRO/EORTC guideline for invasive CSCC treatment formalizes anti-PD-1 (cemiplimab) as standard care for advanced disease while introducing neoadjuvant indications and adjuvant recommendations following high-risk surgery and radiotherapy. The guideline addresses a rapidly evolving area where regulatory approvals (cemiplimab, pembrolizumab) have significantly changed the treatment algorithm.
What the study was
- Study design
- Expert consensus guideline
- Population
- Patients with invasive cutaneous squamous cell carcinoma (CSCC), immunocompetent and immunosuppressed
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- European Journal of Cancer
Why it surfaced
Major European guideline update from a high-authority consortium (EADO/EDF/ESTRO/EORTC) formalizing immunotherapy standards for an increasingly common skin cancer. CSCC incidence is rising, especially in immunosuppressed populations. Guideline publication in EJC by this consortium is directly practice-shaping for European oncology.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.